Related Experiment Videos
beta-Thromboglobulin in patients with acute myocardial infarction according to the treatment
V Dymicka-Piekarska1, H Kemona, M Mantur
1Department of Clinical Laboratory Diagnostics, Medical Academy of Białystok, Białystok, Poland.
Insights
Platelet activation changes during myocardial infarction (MI). Thrombolytic therapy effectively inhibits platelet activation, as indicated by beta-thromboglobulin (beta-TG) levels, suggesting its therapeutic benefit in managing heart disease.
Area of Science:
- Cardiology
- Hematology
- Biochemistry
Background:
- Platelet hyperactivity is a known factor in heart disease, particularly acute myocardial infarction (MI).
- Understanding platelet activation dynamics is crucial for effective MI treatment strategies.
Purpose of the Study:
- To investigate the dynamic changes in beta-thromboglobulin (beta-TG) concentration in patients with MI.
- To assess the influence of disease duration and treatment type on beta-TG levels.
- To evaluate the impact of thrombolytic therapy on platelet activation markers.
Main Methods:
- Study included 29 patients diagnosed with MI, divided into treatment groups.
- Beta-thromboglobulin (beta-TG) concentration was measured using the immunoenzymatic method (ELISA).
- Blood samples were collected on days 1, 3, 5, 8, and 11 post-infarction.
Main Results:
- Significant alterations in platelet activation were observed throughout the course of myocardial infarction.
- Treatment strategies demonstrably affected beta-TG concentrations.
- Thrombolytic therapy was found to significantly inhibit platelet activation.
Conclusions:
- Myocardial infarction is associated with dynamic changes in platelet activation.
- The type of treatment administered influences beta-TG levels in MI patients.
- Thrombolytic therapy shows promise in mitigating platelet activation during MI.
Abstract:
Many studies report on the increased activity of platelets in patients with heart disease, especially with acute myocardial infarction (MI). The aim of the present study was to evaluate dynamics of beta-thromboglobulin (beta-TG) concentration in patients with MI according to the disease duration and type of treatment. We investigated 29 patients, who were divided into two groups according to the type of treatment. beta-TG concentration was determined using the immunoenzymatic method (ELISA). Blood was taken 1st, 3rd, 5th, 8th and 11th day of infarction. Our results indicate that in the course of myocardial infarction there is a change in platelet activation. The treatment applied affects beta-TG concentration, and the thrombolytic therapy inhibits platelet activation.